Compare ABNB & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABNB | BMY |
|---|---|---|
| Founded | 2008 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.7B | 113.5B |
| IPO Year | 2020 | 2006 |
| Metric | ABNB | BMY |
|---|---|---|
| Price | $172.26 | $61.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 44 | 28 |
| Target Price | ★ $183.15 | $65.63 |
| AVG Volume (30 Days) | 3.4M | ★ 11.8M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.00% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | $12,241,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $15.80 | $3.50 |
| Revenue Next Year | $11.65 | N/A |
| P/E Ratio | $30.80 | ★ $21.49 |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $110.81 | $42.52 |
| 52 Week High | $193.45 | $68.64 |
| Indicator | ABNB | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 51.82 |
| Support Level | $126.08 | $59.91 |
| Resistance Level | $187.12 | $62.77 |
| Average True Range (ATR) | 4.30 | 1.81 |
| MACD | 1.37 | 0.50 |
| Stochastic Oscillator | 65.96 | 75.07 |
Airbnb is the world's largest online alternative accommodation travel agency; it also offers booking services for boutique hotels, experiences, and hotel-like services. Airbnb's platform offers over 9 million active accommodation listings. Listings from the company's 5 million-plus hosts are spread over almost every country in the world. In 2025, 42% of revenue was from North America, 39% from Europe, the Middle East, and Africa, 10% from Latin America, and 9% from Asia-Pacific. Transaction fees for online bookings account for all its revenue.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.